AI Robotics in Medicine

Medtronic is moving to broaden U.S. use of its Hugo robotic-assisted surgery system beyond its December urologic clearance, filing 510(k)s for general surgery and gynecologic procedures plus a separate submission for the LigaSure RAS Maryland instrument on the Valleylab FT10 platform.

The bid leans on nearly five years of global use across more than 35 countries, tens of thousands of procedures, and hundreds of independent studies to support broader applicability and meet rising demand for robotic-assisted minimally invasive care already seen at U.S. centers.

Watch whether expanded indications and instrument availability accelerate adoption across additional service lines, shaping how hospitals deploy Hugo beyond urology.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

Geography: United States, European Union, United Kingdom, Canada, Israel, China, Japan, South Korea, Singapore, India, Boston, San Francisco Bay Area, Minneapolis–St. Paul, Houston, London, Cambridge (UK), Berlin, Paris, Zurich, Tel Aviv, Beijing, Shanghai, Shenzhen, Tokyo, Seoul, Bengaluru, Singapore, Toronto, Montreal

1. Medtronic Files 510(k)s to Broaden Hugo RAS Indications in U.S.

Medtronic moved to expand U.S. use of its Hugo robotic-assisted surgery system, which gained FDA clearance in December for urologic procedures and is already used at U.S. medical centers.

The company submitted 510(k) filings to add general surgery and gynecologic procedures, areas it says would “significantly broaden” Hugo’s clinical applicability and meet growing demand for robotic-assisted minimally invasive options.

Medtronic also filed a 510(k) for its LigaSure RAS Maryland instrument, designed for the Valleylab FT10 energy platform on Hugo; the instrument was introduced on Hugo in Europe last year.

The company says Hugo has nearly five years of commercial experience in more than 35 countries across five continents and has been used in tens of thousands of procedures, supported by hundreds of independently published studies.

Key facts:

- Hugo RAS received FDA clearance in December for urologic procedures.

- Medtronic filed 510(k)s to add general and gynecologic surgery indications.

- A 510(k) was submitted for the LigaSure RAS Maryland instrument on Hugo.

- LigaSure technology has been used in over 35 million procedures across 65+ countries.

- Hugo RAS has nearly five years’ commercial use in 35+ countries, tens of thousands of cases.

Why it matters: If cleared, expanded indications would open Hugo to high-volume general and gynecologic surgeries, broadening its U.S. relevance and addressing demand for minimally invasive robotic options.

Integrating proven vessel-sealing technology on the platform could improve surgeon confidence during complex steps, potentially strengthening the system’s value proposition.

What to watch: FDA decisions on the new 510(k) submissions, how quickly U.S. sites adopt the expanded capabilities, and whether additional real-world evidence mirrors the hundreds of published studies supporting safety and effectiveness.

Mpo Mag